Is Hologic, Inc. (HOLX) a Stock to Watch After Gaining 0.70% This Week?

Overall market sentiment has been neutral on Hologic, Inc. (HOLX) stock lately. HOLX receives a Neutral rating from InvestorsObserver Stock Sentiment Indicator.

Hologic, Inc. has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on HOLX!

See Full HOLX Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With HOLX Stock Today?

Hologic, Inc. (HOLX) stock is up 0.75% while the S&P 500 is down -0.15% as of 1:47 PM on Tuesday, Nov 21. HOLX is higher by $0.54 from the previous closing price of $71.90 on volume of 654,734 shares. Over the past year the S&P 500 is higher by 14.96% while HOLX is down -1.52%. HOLX earned $1.83 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 39.5. To see InvestorsObserver's Sentiment Score for Hologic, Inc. click here.

More About Hologic, Inc.

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (64% of total sales, boosted by pandemic), breast health (21% of sales, suppressed by pandemic), surgical (12%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (75%), followed by Europe (16%), Asia (6%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts. Click Here to get the full Stock Report for Hologic, Inc. stock.